The Department of Pharmacology and Immunology has a wide-ranging research portfolio that includes T cell biology and adoptive cellular therapy, neuroimmunology, autoimmunity, alloimmunity, infectious disease, redox metabolism, glycoproteomics, and multimodal spatial omics.
Other strengths in the areas of cancer pharmacology or immunology include T cell biology and metabolism, tumor microenvironment, target discovery, biomarkers, therapy, and the use of immune cells as a vehicle for therapy.
As a result of these research strengths, this newly formed department is anticipated to rank within the top 30th percentile nationally in terms of NIH funding.
The Mass Spectrometry Facility and REDOX Proteomics Core provides LC-MS/MS based analyses for the unbiased discovery of differentially expressed and post-transitionally modified proteins. MALDI-TOF MS, LC-MS, and LC-MS/MS tandem mass spectrometry analyses are offered for protein analysis.
Focused on clinical and translational proteomics, this center advances centralized diagnostic development while leveraging leading MALDI imaging and glycomics capabilities. A collaborative, expert driven environment supports advanced training and discovery that translate proteomic insights into real world impact across research and industry.
Groundbreaking research is being conducted within the Department of Pharmacology & Immunology's 20 laboratories. Award-winning faculty members have access to new or renovated laboratories, with access to core facilities that can serve as functional drivers for trainee research projects.
